Status: Recruiting
Ph 2 Elacestrant in ER Positive Uterine Sarcomas
This study is to evaluate the efficacy and safety of elacestrant, in participants with advanced estrogen receptor (ER)-positive uterine sarcomas. The name of the study drug involved in this research study is: -Elacestrant (a type of selective estrogen receptor degrader)
Participants needed: 30
Trial details
Phase: Phase 2Age: 18+Biological sex: FemaleType: InterventionalSponsor: Dana-Farber Cancer InstituteUpdated: May 22, 2026Locations: 1
Eligibility criteria
True abstinence when this is in line with the preferred and usual lifestyle of t... [+11]